Jeff Johnson
Stock Analyst at Baird
(4.78)
# 118
Out of 4,670 analysts
136
Total ratings
63.04%
Success rate
33.51%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Neutral | $39 → $37 | $30.81 | +20.09% | 14 | Nov 7, 2024 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $22 | $21.48 | +2.42% | 7 | Oct 31, 2024 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $384.85 | +5.24% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $225.89 | +22.18% | 18 | Oct 24, 2024 | |
| PDCO Patterson Companies | Maintains: Neutral | $30 → $28 | $20.46 | +36.85% | 5 | Aug 29, 2024 | |
| COO The Cooper Companies | Maintains: Outperform | $118 → $125 | $100.80 | +24.01% | 15 | Aug 29, 2024 | |
| ALC Alcon | Maintains: Outperform | $104 → $110 | $85.99 | +27.92% | 8 | Aug 22, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $155 → $145 | $110.22 | +31.56% | 13 | Aug 8, 2024 | |
| HSIC Henry Schein | Maintains: Outperform | $92 → $82 | $75.08 | +9.22% | 9 | Aug 7, 2024 | |
| DXCM DexCom | Maintains: Neutral | $80 → $82 | $72.83 | +12.59% | 12 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $262.93 | -9.48% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $46.67 | +49.99% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $19.02 | +220.72% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $18.77 | +256.95% | 6 | Feb 18, 2022 |
Tandem Diabetes Care
Nov 7, 2024
Maintains: Neutral
Price Target: $39 → $37
Current: $30.81
Upside: +20.09%
Envista Holdings
Oct 31, 2024
Maintains: Neutral
Price Target: $17 → $22
Current: $21.48
Upside: +2.42%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $384.85
Upside: +5.24%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $225.89
Upside: +22.18%
Patterson Companies
Aug 29, 2024
Maintains: Neutral
Price Target: $30 → $28
Current: $20.46
Upside: +36.85%
The Cooper Companies
Aug 29, 2024
Maintains: Outperform
Price Target: $118 → $125
Current: $100.80
Upside: +24.01%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $104 → $110
Current: $85.99
Upside: +27.92%
Zimmer Biomet Holdings
Aug 8, 2024
Maintains: Outperform
Price Target: $155 → $145
Current: $110.22
Upside: +31.56%
Henry Schein
Aug 7, 2024
Maintains: Outperform
Price Target: $92 → $82
Current: $75.08
Upside: +9.22%
DexCom
Aug 5, 2024
Maintains: Neutral
Price Target: $80 → $82
Current: $72.83
Upside: +12.59%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $262.93
Upside: -9.48%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $46.67
Upside: +49.99%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $19.02
Upside: +220.72%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $18.77
Upside: +256.95%